Standard BioTools Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
389
- Stock Symbol
-
LAB
- Investments
-
6
- Share Price
-
$0.62
- (As of Monday Closing)
Standard BioTools General Information
Description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Contact Information
Website
www.standardbio.comCorporate Office
- 50 Milk Street
- 10th Floor
- Boston, MA 02109
- United States
Corporate Office
- 50 Milk Street
- 10th Floor
- Boston, MA 02109
- United States
Standard BioTools Stock Performance
As of 16-Nov-2026, Standard BioTools’s stock price is $0.62. Its current market cap is $245M with 395M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.62 | $0.70 | $0.59 - $1.72 | $245M | 395M | 1.17M | $0.34 |
Standard BioTools Financials Summary
As of 30-Sep-2026, Standard BioTools has a trailing 12-month revenue of $84.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (157,888) | 324,730 | 374,597 | 450,830 |
| Revenue | 84,430 | 85,331 | 91,008 | 106,340 |
| EBITDA | (82,517) | (94,878) | (90,419) | (60,029) |
| Net Income | 133,076 | (74,896) | (138,885) | (74,656) |
| Total Assets | 635,332 | 567,754 | 612,345 | 323,067 |
| Total Debt | 26,834 | 30,827 | 30,695 | 98,210 |
Standard BioTools Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Standard BioTools Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Standard BioTools Comparisons
Industry
Financing
Details
Standard BioTools Competitors (25)
One of Standard BioTools’s 25 competitors is 10x Genomics, a Formerly VC-backed company based in Pleasanton, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 10x Genomics | Formerly VC-backed | Pleasanton, CA | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| Sphere Fluidics | Formerly VC-backed | Cambridge, United Kingdom | ||||
| ToolGen | Formerly VC-backed | Seoul, South Korea |
Standard BioTools Patents
Standard BioTools Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025235792-A1 | Compositions and methods for detecting allelic variants | Pending | 10-May-2024 | ||
| WO-2025235787-A1 | Methods and compositions for the analysis of nucleic acids | Pending | 10-May-2024 | ||
| WO-2025235787-A8 | Methods and compositions for the analysis of nucleic acids | Pending | 10-May-2024 | ||
| EP-4612481-A2 | High throughput optical imager | Pending | 03-Nov-2022 | ||
| EP-4612481-A4 | High throughput optical imager | Pending | 03-Nov-2022 | G02B21/16 |
Standard BioTools Signals
Standard BioTools Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Standard BioTools Investments & Acquisitions (6)
Standard BioTools’s most recent deal was a Reverse Merger with Treeline Biosciences Holdings. The deal was made on 20-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Treeline Biosciences Holdings | 20-Jul-2026 | Reverse Merger | Drug Discovery | ||
| Sengenics | 21-Nov-2024 | Merger/Acquisition | Other Healthcare Services | ||
| SomaLogic Operating Company | 05-Jan-2024 | Merger/Acquisition | Biotechnology | ||
| InstruNor | 17-Jan-2020 | Merger/Acquisition | Diagnostic Equipment | ||
| DVS Sciences | 13-Feb-2014 | Merger/Acquisition | Discovery Tools (Healthcare) |
Standard BioTools ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
21.62 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Standard BioTools Exits (1)
Standard BioTools’s most recent exit was on 05-Jan-2024 from SomaLogic Operating Company. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SomaLogic Operating Company | 05-Jan-2024 | Completed |
|
Standard BioTools Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sengenics | Boulder, CO | 2008 | |
| Standard BioTools (Mass Cytometry Business) | Boston, MA |
Standard BioTools FAQs
-
When was Standard BioTools founded?
Standard BioTools was founded in 1999.
-
Where is Standard BioTools headquartered?
Standard BioTools is headquartered in Boston, MA.
-
What is the size of Standard BioTools?
Standard BioTools has 389 total employees.
-
What industry is Standard BioTools in?
Standard BioTools’s primary industry is Discovery Tools (Healthcare).
-
Is Standard BioTools a private or public company?
Standard BioTools is a Public company.
-
What is Standard BioTools’s stock symbol?
The ticker symbol for Standard BioTools is LAB.
-
What is the current stock price of Standard BioTools?
As of 16-Nov-2026 the stock price of Standard BioTools is $0.62.
-
What is the current market cap of Standard BioTools?
The current market capitalization of Standard BioTools is $245M.
-
What is Standard BioTools’s current revenue?
The trailing twelve month revenue for Standard BioTools is $84.4M.
-
Who are Standard BioTools’s competitors?
10x Genomics, Illumina, Twist Bioscience, Sphere Fluidics, and ToolGen are some of the 25 competitors of Standard BioTools.
-
What is Standard BioTools’s annual earnings per share (EPS)?
Standard BioTools’s EPS for 12 months was $0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process